EP3643301A1 — Apixaban formulations
Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2020-04-29 · 6y expired
What this patent protects
The present invention provides tablets comprising a composition comprising crystalline apixaban particles having a mean particle size equal to or less than about 85 µm and a D 90 equal to or less than 85 µm and further comprising a pharmaceutically acceptable diluent or carrier …
USPTO Abstract
The present invention provides tablets comprising a composition comprising crystalline apixaban particles having a mean particle size equal to or less than about 85 µm and a D 90 equal to or less than 85 µm and further comprising a pharmaceutically acceptable diluent or carrier as well as processes for producing the same.
Drugs covered by this patent
- Eliquis (apixaban) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.